This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Retail Sales Came in Better Than Expected
by Zacks Equity Research
Retail Sales Came in Better Than Expected
Econ Reports, Q2 Earnings Take July Rate Cut Off the Table
by Mark Vickery
Any investors still hoping for a July rate cut based on economic prints, we can uncross our fingers now.
Morgan Stanley (MS) Q2 Earnings Beat on Robust IB & Trading
by Zacks Equity Research
The resurgence of the capital markets businesses majorly supports Morgan Stanley's (MS) Q2 earnings, while the muted wealth management business acts as a spoilsport.
Morgan Stanley (MS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Morgan Stanley (MS) delivered earnings and revenue surprises of 10.30% and 5.95%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Dow Closes at New High as Q2 Earnings Season Heats Up
by Mark Vickery
Earnings season only picks up steam in the weeks to come.
A Big Week in the USA: Global Week Ahead
by John Blank
Inflation and higher rates have tested the resilience of households as signs of a cooling economy and inflation bolster expectations for rate cuts to start in September.
IB, Trading to Support Morgan Stanley's (MS) Q2 Earnings
by Zacks Equity Research
Morgan Stanley's (MS) second-quarter 2024 earnings are expected to have been positively impacted by a decent trading performance.
Morgan Stanley (MS) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the most recent trading session, Morgan Stanley (MS) closed at $104.09, indicating a -0.53% shift from the previous trading day.
Are You Looking for a High-Growth Dividend Stock?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Morgan Stanley (MS) have what it takes? Let's find out.
The Zacks Analyst Blog Highlights Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri
by Zacks Equity Research
Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri are part of the Zacks top Analyst Blog.
Morgan Stanley (MS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Morgan Stanley (MS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Top Analyst Reports for Danaher, Morgan Stanley & Pfizer
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Morgan Stanley (MS) and Pfizer Inc. (PFE), as well as two micro-cap stocks, Elite Pharmaceuticals, Inc. (ELTP) and Oil-Dri Corporation of America (ODC).
Seeking Clues to Morgan Stanley (MS) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Morgan Stanley (MS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Here's Why Morgan Stanley (MS) Gained But Lagged the Market Today
by Zacks Equity Research
Morgan Stanley (MS) closed at $103.46 in the latest trading session, marking a +0.83% move from the prior day.
How Will Bank ETFs Perform in Light of Q2 Earnings?
by Sanghamitra Saha
Big banks will start releasing their quarterly numbers this week.
Morgan Stanley (MS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Morgan Stanley (MS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Truist (TFC) Declares SCB, Rewards Shareholders With Buyback Plan
by Zacks Equity Research
Truist's (TFC) board of directors has approved a share repurchase authorization worth $5 billion through 2026, following the clearance of the 2024 stress test.
Citizens Financial (CFG) Declares SCB & Planned Capital Actions
by Zacks Equity Research
Citizens Financial (CFG) expands share repurchase plan by $656 million following the stress test results. Given the company's solid balance sheet and decent liquidity profile, this seems sustainable.
The Zacks Analyst Blog Highlights JPMorgan, Goldman Sachs, Wells Fargo, Morgan Stanley, Bank of America, Citigroup and Fifth Third
by Zacks Equity Research
JPMorgan, Goldman Sachs, Wells Fargo, Morgan Stanley, Bank of America, Citigroup and Fifth Third are included in this Analyst Blog.
Banks Clear 2024 Stress Test: Will Payouts be Bigger This Time?
by Swayta Shah
This year, all 31 banks, including JPMorgan, Goldman, Morgan Stanley, Citigroup and Fifth Third Bancorp, have cleared the stress test. The payouts are likely to be conservative due to lingering headwinds.
Why Morgan Stanley (MS) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Morgan Stanley (MS) have what it takes? Let's find out.
Morgan Stanley (MS) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
Morgan Stanley (MS) reachead $97.80 at the closing of the latest trading day, reflecting a +0.72% change compared to its last close.
Large Banks to be Conservative About Shareholder Payouts
by Swayta Shah
The 2024 stress test results are due this Wednesday. So, banks - JPMorgan (JPM), Goldman (GS), Morgan Stanley (MS), Bank of America (BAC) and Citizens Financial Group (CFG) - are in the spotlight.
Morgan Stanley (MS) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Morgan Stanley (MS) reachead $97.10 at the closing of the latest trading day, reflecting a +0.98% change compared to its last close.
JPMorgan (JPM) Announces Plans to Expand in South Florida
by Zacks Equity Research
Being one of JPMorgan's (JPM) key strategic regions in the country, the bank announces plans to expand in South Florida.